| pubmed-article:21204910 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21204910 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21204910 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:21204910 | lifeskim:mentions | umls-concept:C0439849 | lld:lifeskim |
| pubmed-article:21204910 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:21204910 | lifeskim:mentions | umls-concept:C0011015 | lld:lifeskim |
| pubmed-article:21204910 | lifeskim:mentions | umls-concept:C0683150 | lld:lifeskim |
| pubmed-article:21204910 | lifeskim:mentions | umls-concept:C2828008 | lld:lifeskim |
| pubmed-article:21204910 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:21204910 | pubmed:dateCreated | 2011-3-14 | lld:pubmed |
| pubmed-article:21204910 | pubmed:abstractText | It has been shown that the cellular uptake and cytotoxicity of anthracyclines decrease with increasing cell density in vitro, an event termed 'the inocculum effect'. It is not known whether such an effect occurs in vivo. In this study the relationships between white blood cell (WBC) count, plasma and cellular concentrations of daunorubicin (DNR) in patients with acute myeloid leukaemia were investigated. | lld:pubmed |
| pubmed-article:21204910 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21204910 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21204910 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21204910 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21204910 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21204910 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21204910 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:21204910 | pubmed:issn | 1365-2125 | lld:pubmed |
| pubmed-article:21204910 | pubmed:author | pubmed-author:GruberAstridA | lld:pubmed |
| pubmed-article:21204910 | pubmed:author | pubmed-author:KarlssonMats... | lld:pubmed |
| pubmed-article:21204910 | pubmed:author | pubmed-author:PaulChristerC | lld:pubmed |
| pubmed-article:21204910 | pubmed:author | pubmed-author:MasquelierMic... | lld:pubmed |
| pubmed-article:21204910 | pubmed:author | pubmed-author:VitolsSigurdS | lld:pubmed |
| pubmed-article:21204910 | pubmed:author | pubmed-author:LafoliePierre... | lld:pubmed |
| pubmed-article:21204910 | pubmed:author | pubmed-author:BogasonAlexA | lld:pubmed |
| pubmed-article:21204910 | pubmed:author | pubmed-author:QuartinoAngel... | lld:pubmed |
| pubmed-article:21204910 | pubmed:copyrightInfo | © 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society. | lld:pubmed |
| pubmed-article:21204910 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21204910 | pubmed:volume | 71 | lld:pubmed |
| pubmed-article:21204910 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21204910 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21204910 | pubmed:pagination | 514-21 | lld:pubmed |
| pubmed-article:21204910 | pubmed:meshHeading | pubmed-meshheading:21204910... | lld:pubmed |
| pubmed-article:21204910 | pubmed:meshHeading | pubmed-meshheading:21204910... | lld:pubmed |
| pubmed-article:21204910 | pubmed:meshHeading | pubmed-meshheading:21204910... | lld:pubmed |
| pubmed-article:21204910 | pubmed:meshHeading | pubmed-meshheading:21204910... | lld:pubmed |
| pubmed-article:21204910 | pubmed:meshHeading | pubmed-meshheading:21204910... | lld:pubmed |
| pubmed-article:21204910 | pubmed:meshHeading | pubmed-meshheading:21204910... | lld:pubmed |
| pubmed-article:21204910 | pubmed:meshHeading | pubmed-meshheading:21204910... | lld:pubmed |
| pubmed-article:21204910 | pubmed:meshHeading | pubmed-meshheading:21204910... | lld:pubmed |
| pubmed-article:21204910 | pubmed:meshHeading | pubmed-meshheading:21204910... | lld:pubmed |
| pubmed-article:21204910 | pubmed:meshHeading | pubmed-meshheading:21204910... | lld:pubmed |
| pubmed-article:21204910 | pubmed:meshHeading | pubmed-meshheading:21204910... | lld:pubmed |
| pubmed-article:21204910 | pubmed:meshHeading | pubmed-meshheading:21204910... | lld:pubmed |
| pubmed-article:21204910 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21204910 | pubmed:articleTitle | Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia. | lld:pubmed |
| pubmed-article:21204910 | pubmed:affiliation | Departments of Medicine, Divisions of Clinical Pharmacology, Karolinska Institute/Karolinska University Hospital, Solna S-171 76, Stockholm, Sweden. | lld:pubmed |
| pubmed-article:21204910 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21204910 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
